EUVIMEDEUVIMED entdecken
Crossref

Clinical features of medication‐related osteonecrosis of the jaw in prostate cancer management

Yuma Goto, Fumihiko Urabe iD, Yue Ogihara, Mana Nakata, Juria Nakano, Kensuke Fujiwara, Masaki Hashimoto, Yuhei Koike, Yuya Iwamoto, Keiichiro Miyajima, Wataru Fukuokaya iD, Kosuke Iwatani und 10 weitere

BJU International · 2025

DOI: 10.1111/bju.16860 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJU International, 2025. Verfasst von Yuma Goto und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Denosumab, Bone Neoplasms, Bisphosphonate-Associated Osteonecrosis of the Jaw. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the cumulative incidence of medication‐related osteonecrosis of the jaw (MRONJ) in patients with prostate cancer and bone metastases receiving long‐term denosumab treatment, and also the occurrence of severe MRONJ and risk factors associated with the development of both MRONJ and severe MRONJ. Patients and Methods This retrospective study included 624 patients with prostate cancer and bone metastases treated with denosumab between January 2015 and December 2024. Patients without bone metastasis or with insufficient clinical data were excluded. The study assessed the cumulative incidence of MRONJ, as well as risk factors associated with MRONJ of any stage and severe MRONJ (Stage ≥2). Cox regression analysis was used to identify independent risk factors.

Results

The cumulative incidence of MRONJ at 1, 2, 3, and 6 years was 4.6%, 9.6%, 20.3%, and 51.9%, respectively. For severe MRONJ, the corresponding rates were 2.4%, 6.7%, 13.1%, and 27.9%, respectively. Multivariate analysis identified the following independent risk factors for MRONJ: extent of disease grade ≥3 (hazard ratio [HR] 2.00, P = 0.009), use of anticoagulants and/or antiplatelets (HR 2.08, P = 0.026), and a history of dental treatment within the past 6 months (HR 2.29, P = 0.003). Denosumab administration at intervals >1 month was associated with a reduced risk (HR 0.46, P = 0.041).

Conclusion

This study demonstrates that long‐term denosumab treatment in patients with prostate cancer and bone metastases is associated with a substantial cumulative incidence of MRONJ. Key risk factors were identified, along with a modifiable factor that may reduce risk. These findings suggest that adjusting denosumab dosing schedules could help mitigate MRONJ risk, underscoring the need for personalised treatment plans and early preventive strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsDenosumabBone NeoplasmsBisphosphonate-Associated Osteonecrosis of the JawBone Density Conservation AgentsHumansMaleRetrospective StudiesAgedMiddle AgedRisk FactorsIncidenceAged, 80 and over

Stichwörter der Autor:innen

JIKEI‐YAYOIMRONJdenosumabmCRPCmCSPCmedication‐related osteonecrosis of the jawprostate cancer

Substanzen

DenosumabBone Density Conservation Agents

Autor:innen und Institutionen

  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Urology, Jikei the 3rd Hospital, Tokyo, Japan.
  • Department of Urology, JR Tokyo General Hospital, Tokyo, Japan.
  • Department of Urology, Machida Municipal Hospital, Tokyo, Japan.
  • Department of Urology, Jikei Katsushika Medical Center, Tokyo, Japan.
  • Department of Urology, Atsugi City Hospital, Atsugi, Kanagawa, Japan.

ORCID-Profile: Fumihiko Urabe, Wataru Fukuokaya, Takafumi Yanagisawa, Jun Miki

Zitieren

APA

Goto, Y., Urabe, F., Ogihara, Y., Nakata, M., Nakano, J., Fujiwara, K., Hashimoto, M., Koike, Y., Iwamoto, Y., Miyajima, K., Fukuokaya, W., Iwatani, K., Imai, Y., Inaba, Y., Ito, K., Yanagisawa, T., Murakami, M., Tashiro, K., Watanabe, K., …, & JIKEI‐YAYOI Collaborative Group (2025). Clinical features of medication‐related osteonecrosis of the jaw in prostate cancer management. BJU International. https://doi.org/10.1111/bju.16860

Vancouver

Goto Y, Urabe F, Ogihara Y, Nakata M, Nakano J, Fujiwara K, et al. Clinical features of medication‐related osteonecrosis of the jaw in prostate cancer management. BJU International. 2025. doi:10.1111/bju.16860

BibTeX
@article{Goto2025,
  author = {Goto, Yuma and Urabe, Fumihiko and Ogihara, Yue and Nakata, Mana and Nakano, Juria and Fujiwara, Kensuke and Hashimoto, Masaki and Koike, Yuhei and Iwamoto, Yuya and Miyajima, Keiichiro and Fukuokaya, Wataru and Iwatani, Kosuke and Imai, Yu and Inaba, Yuzo and Ito, Kagenori and Yanagisawa, Takafumi and Murakami, Masaya and Tashiro, Kojiro and Watanabe, Katsuhito and Miki, Jun and Kimura, Takahiro and JIKEI‐YAYOI Collaborative Group, JIKEI‐YAYOI Collaborative Group},
  title = {Clinical features of medication‐related osteonecrosis of the jaw in prostate cancer management},
  journal = {BJU International},
  year = {2025},
  doi = {10.1111/bju.16860}
}
Kostenlos starten →